Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study

Shugang Cao,Hai Yu,Jingluan Tian,Yuanyuan Li,Yueping Shen,Xiaopei Ji,Xiaoyuan Wang,Xiaoling Zhou,Yanzheng Gu,Feng Zhu,Xiaoyu Duan,Xinyi Xiao,Qi Fang,Xiangjun Chen,Qun Xue

Journal of the Neurological Sciences（2021）

引用 3|浏览15

暂无评分

摘要

•mRTX was better than AZA but comparable to MMF in reducing NMOSD relapse.•mRTX-treated patients showed less concomitant steroids use and fewer adverse events.•Relapse before immunosuppressant therapy could increase the NMOSD relapse risk.

查看译文

关键词

Neuromyelitis optica spectrum disorder,Rituximab,Azathioprine,Mycophenolate mofetil,Annualized relapse rate,Safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要